Actelion Planning Phase II For Endothelin Antagonist Licensed From Roche
Executive Summary
The biotech start-up Actelion expects that its endothelin antagonist RO 61-0612 will enter Phase II in July, CEO Thomas Widman, MD, told an April 28 session of the Ernst & Young/Atlas Venture conference in Amsterdam.